ASSOCIATION FOR ACCESSIBLE MEDICINES

Lobbying for ASSOCIATION FOR ACCESSIBLE MEDICINES

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Expenses

$650,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 16

Centers For Medicare and Medicaid Services (CMS)
Commerce, Dept of (DOC)
Congressional Budget Office (CBO)
Federal Trade Commission (FTC)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Natl Economic Council (NEC)
Office of Management & Budget (OMB)
Office of Science & Technology Policy (OSTP)
Office of the Vice President of the United States
SENATE
State, Dept of (DOS)
U.S. Customs & Border Protection
U.S. Trade Representative (USTR)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 28

HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
HR 1396
PILLS Act
S 1891
PILLS Act
S 1954
Biosimilar Red Tape Elimination Act
HR 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application subm…
HR 3955
RAPID Reserve Act
S 2062
RAPID Reserve Act
HR 6992
MAPS Act
S 1784
MAPS Act
HR 4132
Prescription Information Modernization Act of 2025
S 2027
Prescription Information Modernization Act of 2025
S 1414
Expedited Access to Biosimilars Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 3160
PREVAIL Act
S 1553
PREVAIL Act
HR 3152
Patent Eligibility Restoration Act of 2025
S 1546
Patent Eligibility Restoration Act of 2025
HR 3269
ETHIC Act
S 1041
Affordable Prescriptions for Patients Act
S 1095
Stop STALLING Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 43
Skinny Labels, Big Savings Act
S 1040
Drug Competition Enhancement Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
HR 2213
Medical Supply Chain Resiliency Act
S 998
Medical Supply Chain Resiliency Act
HR 1980
State Strategic Stockpile Act of 2025

Lobbying activity 4

Pharmacy

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. S.1954: Biosimilar Red Tape Elimination Act. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062 - RAPID Reserve Act. H.R.6992/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025.

Medicare/Medicaid

Medicare Part D Reform. S.1414: Expedited Access to Biosimilars Act. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation. H.R.1: One Big Beautiful Bill Act as it relates to Delinking in Medicare Part D, Medicaid Spread Pricing, PBM transparency, and NADAC Reporting.

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269: Eliminating Thickets to Increase Competition (ETHIC) Act. S.1041: Affordable Prescriptions for Patients Act. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act. S.1097: Interagency Patent Coordination and Improvement Act of 2025.

Trade (domestic/foreign)

General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. H.R.2213/S.998: Medical Supply Chain Resiliency Act. H.R.1980: State Strategic Stockpile Act of 2025.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.